BMS Just Bet $15 Billion on China's Drug Pipeline

Bloomberg noted that BMS is "seeking to leverage China's efficiency in early development." Translation: why pay American prices for Phase 1 work when someone else can do it quicker?

Why BMS Needs This Deal

Bristol Myers Squibb has a problem that no single deal can fix, but every deal helps: the patent cliff.

Blockbuster drugs like Revlimid and Eliquis are losing (or have lost) exclusivity, and the revenue those products generated needs to be replaced. That slow bleed demands constant pipeline replenishment.

BMS has been on an acquisition tear to address this. In 2024 alone, it closed deals for Mirati Therapeutics (KRAS-targeted cancer drugs), RayzeBio (radiopharmaceuticals), and Karuna Therapeutics (schizophrenia treatment). In 2025, it agreed to acquire Orbital Therapeutics for its RNA immunotherapy platform and inked a major bispecific antibody deal with BioNTech.

More than 60% of BMS's current development pipeline comes from outside the company. The Hengrui deal is the latest, and largest, expression of that strategy. When your own labs can't fill the gap fast enough, you shop globally.

Wall Street's Verdict: A Shrug, Not a Standing Ovation

BMO Capital Markets reiterated a Market Perform rating after the announcement and nudged its price target up to $60 (the stock was trading around $56-57). The message was clear: this is incrementally positive, not transformational.

Analysts see the deal as a tool to "address Bristol's upcoming loss of exclusivity challenges," but BMO stressed that "more work needs to be done." Running 13 partnered programs at once raises real concerns about operational complexity, especially for a company carrying significant debt and facing flat-to-declining earnings.

The Street's posture is cautiously constructive. If several Hengrui programs pan out, BMS could see a meaningful re-rating. If they don't, the company just added complexity to an already complicated story.

The Elephant in the Room: Geopolitics

A $15 billion China deal in 2026 doesn't happen in a vacuum. It happens against the backdrop of the BIOSECURE Act, which restricts U.S. government agencies from contracting with certain designated Chinese biotech companies. It happens while the COINS Act gives the Treasury Department authority to screen outbound investments in sensitive sectors. And it happens as Congress debates BINSA, a bipartisan bill that would explicitly pull pharmaceutical licensing deals with Chinese firms into formal national security review.

None of these laws currently block a deal like BMS-Hengrui. The BIOSECURE Act targets government procurement, not private licensing. BINSA remains a discussion draft. But the trajectory is unmistakable: regulatory touchpoints for cross-border biopharma deals are multiplying.

Industry advisors now recommend that deal teams map their exposure to tariffs, export controls, BIOSECURE, and potential BINSA implications before signing. Contracts increasingly include "switch-out" rights, allowing companies to move manufacturing or data services away from designated firms if the regulatory landscape shifts.

BMS structured this deal as a licensing collaboration, not an acquisition, which provides some insulation. But if BINSA passes and biotech licensing gets pulled into outbound investment screening, future deals of this kind could face much longer timelines and heavier scrutiny.

The Bigger Picture: China's Pharma Export Boom

Hengrui isn't just partnering with BMS. In July 2025, it signed a deal with GSK worth up to $12 billion. It has agreements with Merck & Co. and Hansoh. Meanwhile, other Chinese firms are inking massive cross-border transactions: Eli Lilly partnered with Innovent for $8.9 billion; AbbVie licensed assets from RemeGen for up to $5.6 billion.

China's biopharma sector has evolved from a generics factory into a genuine source of novel drug candidates. Hengrui alone has over 100 proprietary innovative candidates in clinical development across more than 400 trials globally. Western pharma companies aren't partnering with Chinese firms out of charity; they're doing it because the science is real and the speed is unmatched.

The BMS-Hengrui deal is a bet that this trend accelerates, even as the political winds blow the other direction. It's a calculated gamble: buy access to China's R&D engine while you still can, structure the economics so you only pay big if the drugs deliver, and hope that Washington doesn't slam the door shut before the pipeline matures.

For BMS, the next few years will determine whether this was a prescient strategic move or an expensive exercise in complexity management. For the broader industry, it's a signal that the integration of Chinese pharmaceutical innovation into global pipelines isn't slowing down. It's speeding up.

The First Toddlers Eligible for CRISPR Are Two Years Old

The FDA just approved a CRISPR gene therapy for kids as young as two, making Casgevy the first gene-editing treatment cleared for toddlers with sickle cell disease or beta thalassemia. The approval took just 53 days, and the implications stretch far beyond the 5,500 newly eligible children.